Cladribine
- Generic Name
- Cladribine
- Brand Names
- Litak, Mavenclad
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12ClN5O3
- CAS Number
- 4291-63-8
- Unique Ingredient Identifier
- 47M74X9YT5
- Background
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
- Indication
For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Non-Hodgkin's Lymphomas, Active confirmed by clinical features, confirmed by imaging features relapsing multiple sclerosis (MS)
- Associated Therapies
- -
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
- Conditions
- Hairy Cell Leukemia
- Interventions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 203
- Registration Number
- NCT00923013
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: rituximabDrug: cladribineDrug: temsirolimusBiological: FilgrastimBiological: Pegfilgrastim
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 74
- Registration Number
- NCT00787969
- Locations
- 🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸Bismarck Cancer Center, Bismarck, North Dakota, United States
🇺🇸St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
- Conditions
- Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Indolent Adult Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRefractory B-Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 57
- Registration Number
- NCT00764517
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
Oral Cladribine in Early Multiple Sclerosis (MS)
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2021-03-22
- Target Recruit Count
- 617
- Registration Number
- NCT00725985
- Locations
- 🇺🇸
Multiple Sclerosis Center Drive, Neurology Suite 701, Newport Beach, California, United States
🇺🇸MS Center of Brevard MIMA Centry Research Associates, Melbourne, Florida, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 128
- Registration Number
- NCT00718549
- Locations
- 🇧🇾
City Clinical Hospital #9, Minsk, Belarus
🇵🇱Szpital Uniwersytecki W Krakowie; Klinika Hematologii, Krakow, Poland
🇵🇱Medical University, Independent Public Clinical Hospital; Dept. of Hematology, SPSK, Bialystok, Poland
Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
- Conditions
- Lymphoma of Mucosa-Associated Lymphoid Tissue
- Interventions
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 40
- Registration Number
- NCT00656812
- Locations
- 🇦🇹
Universitätsklinikum Graz, Graz, Austria
🇦🇹Krankenhaus der Stadt Linz, Linz, Austria
🇦🇹AKH Wien / Universitaetsklinik fuer Innere Medizin I, Vienna, Austria
CLARITY Extension Study
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Drug: PlaceboDrug: Cladribine
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2020-12-07
- Target Recruit Count
- 867
- Registration Number
- NCT00641537
- Locations
- 🇬🇧
Research Site, Stoke-on-Trent, United Kingdom
🇷🇺Reseach Site, Saratov, Russian Federation
2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2007-06-06
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT00483067
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2020-10-12
- Target Recruit Count
- 172
- Registration Number
- NCT00436826
- Locations
- 🇪🇸
Research Site, Seville, Spain
🇪🇸Research site, Barcelona, Spain
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- Conditions
- Hairy Cell LeukemiaRecurrent Hairy Cell Leukemia
- Interventions
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT00412594
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.